O
2.53
0.10 (4.24%)
| Penutupan Terdahulu | 2.43 |
| Buka | 2.45 |
| Jumlah Dagangan | 13,074 |
| Purata Dagangan (3B) | 686,777 |
| Modal Pasaran | 21,044,158 |
| Harga / Jualan (P/S) | 0.130 |
| Harga / Buku (P/B) | 0.080 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 May 2024 |
| Margin Operasi (TTM) | -300.33% |
| EPS Cair (TTM) | -87.25 |
| Nisbah Semasa (MRQ) | 0.100 |
| Aliran Tunai Operasi (OCF TTM) | -15.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -6.06 M |
| Pulangan Atas Aset (ROA TTM) | -21.85% |
| Pulangan Atas Ekuiti (ROE TTM) | -1,758.48% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Onconetix, Inc. | - | - |
AISkor Stockmoo
0.0
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 57.93% |
| % Dimiliki oleh Institusi | 7.86% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |